PA

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Krzesinski J–M et al. – The amlodipine/valsartan combination is an association of two well–known antihypertensive products with specific targets in cardiovascular protection, namely calcium channel blockade and antagonism of the renin–angiotensin–aldosterone system. This kind of association, with neutral metabolic properties and significant antihypertensive efficacy, could be a useful new antihypertensive product. Currently available data have shown that this new combination is well–tolerated and effective even in severe hypertension. Clinical trials are ongoing for further assessment of the efficacy, compliance, and safety of this combination and its congeners. No data exist to prove that the amlodipine/valsartan combination is better than other antihypertensive strategies for cardiovascular or renal protection, but some trials with other combination therapies show such potential advantage.


Related Articles

Amlodipine/Valsartan Single-Pill Combination: A Review of its Use in the Management of Hypertension
American Journal of Cardiovascular Drugs, 10/08/09    Relevance Score: 84%

Today in Clinical Pharmacology...keeping you current

Olanzapine versus other atypical antipsychotics for schizophrenia
Cochrane Reviews, 03/19/10

Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis
Cochrane Reviews, 03/19/10

Fibrinolytic agents for peripheral arterial occlusion
Cochrane Reviews, 03/19/10

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address